Patients like Lara inspire us to continue pushing the limits of possibility. Read her full story on p. 35.
Your support provides funds that fuel education and clinical care that benefits patients all around the world.
Message From Our Leaders

History is written at The Princess Margaret. From the identification of the stem cell by Drs. Till and McCulloch in the 1960s to Dr. De Carvalho’s 2017 discovery of a mechanism that could potentially trigger an immune response to fight colorectal cancer cells, we have always been driving innovation. We continue to break down barriers and forge into new territory, despite uncertainties that may lie ahead. We have always had the Courage to Conquer.

Now we are in a new period of history, one full of uncertainty. The unprecedented COVID-19 pandemic has impacted the entire world, bringing with it challenges that none of us expected. But one thing is certain: cancer has not stopped with the spread of COVID-19, and neither will we.

This year we delivered the first phase of our strategic plan, built on the strong legacy and foundation we have in place. Our focus has been positioning our organization to aim higher, reach further, and deliver on our mission to enable Future Care Now at The Princess Margaret.

The Princess Margaret Cancer Foundation hit a milestone in 2020, with $140 million in net fundraising and lottery revenue. We expanded our national and international fundraising partnerships to set the groundwork for broader impact in the years to come, including a $10 million commitment from Michael McCain to expand the McCain GU (Genito-Urinary) Biobank and a $2.5 million donation from Maple Leaf Foods that started The Frontline Fund. The Biobank will advance internationally leading urologic cancer research by providing high-quality specimens and clinical data to researchers here in Canada and around the world. The Princess Margaret Home Lottery also set a new record this year by delivering our largest lottery in history with $41.6 million in net revenue while The Enbridge® Ride to Conquer Cancer® raised an impressive $18.2 million. To accompany our Foundation’s fundraising success, we also realized $29.7 million in returns from our investments in the commercialization of two cancer drugs developed at The Princess Margaret. That money will now be reinvested in research and innovation at our research institute.

Despite our progress, we know that COVID-19 has brought uncertainty and concern. Our Board of Directors remains committed to ensuring that our organization is strong and resilient, with diversified fundraising programs, strong internal operations and robust governance so we can continue to provide our world-leading clinicians and researchers with the resources they need to remain at the forefront of transformational progress. As one of the top 5 cancer research centres in the world, we are relentless in our pursuit of groundbreaking cancer research and innovation.

This year has presented challenges that none of us anticipated, but the funds raised by our programs will move us forward as we write this new chapter in cancer research history. We’d like to thank our donors, volunteers and community members for their dedication, generosity and support. Together, we remain fearless in our Courage to Conquer.

Janice Fukakusa, Board Chair of The Princess Margaret Cancer Foundation and Michael Burns, President & CEO of The Princess Margaret Cancer Foundation
Delivering the Plan to
Enable Future Care Now
at The Princess Margaret

A lot has happened in the past year, around the world as well as here at The Princess Margaret Cancer Foundation. But our mission remains the same: enable Future Care Now by raising funds that accelerate cancer research, education and clinical care that benefits patients at Princess Margaret Cancer Centre, across Canada and around the world.

In fiscal year 2020, we delivered the first year of our new Foundation strategic plan – Strategic Plan 2025: The Roadmap to Enabling Future Care Now.

We are committed to ensuring that our organization continues to be resilient and positioned for growth, and is the most impactful place a donor can invest for the future of cancer care and research.

Our generous donors deepened their commitment this year to support leading-edge cancer research and care at The Princess Margaret with more than $60 million in donations to The Foundation, the Princess Margaret Home Lottery set a new record again this year, with the largest lottery in the history of The Foundation, raising $41.6 million in net revenue. The Enbridge® Ride to Conquer Cancer® raised an impressive $18.2 million, leading the way to more than $32.4 million gross revenue across all our events. To accompany our Foundation’s fundraising success, we also realized $29.7 million in revenue from fundraising, net revenue from the lottery innovation at our research institute. With the total net revenue from our investments in the commercialization of two cancer drugs developed at The Princess Margaret.

That money will now be reinvested in research and development. In addition to delivering on our fundraising programs, our internal focus has been on elevating the fundraising capacity of our organization so we can accelerate groundbreaking cancer research and care. This year we completed a full review of our governance program, began developing new fundraising programs that would create more opportunities for donors to support The Princess Margaret, and delivered critical work that modernizes our internal systems and positions our organization for growth.

We have also recruited new talent, with strong functional expertise and a deep commitment to our mission. We continue to strengthen our team by recruiting leaders from the private and charitable sectors, and we are working to bring greater diversity to our management and Board. Within our Foundation team, 47% of staff are visible minorities and 72% are women; 63% of roles, director and above, are held by women. This diversity brings us significant strength, and our Board of Directors has ensured that our organization is well positioned to withstand this shock, and that we can continue to drive toward greater diversity and inclusion, specifically within senior management and our Board of Directors, and we are committed to championing this in the year ahead.

Finally, we have begun to develop national and international fundraising partnerships to strengthen our impact in global cancer research. This year we announced our partnership with The Marathon of Hope Cancer Research Network, a pan-Canadian network of designated research centres that will share knowledge, harness technology and improve collaboration toward finding cures for cancer. We also began discussions with The XPRIZE Foundation, the Davidoff Cancer Centre in Israel, and A.C. Camargo in Brazil, with the objective of developing fundraising projects to support collaborative research and accelerate the global cancer research of our respective organizations.

If the COVID-19 pandemic has taught the charitable sector anything, it is that we must be more resilient to uncertainty and unprecedented events. Charities have long been solely evaluated on their expense ratios, with less consideration for their ability to fulfill their mission and deliver impact over the long-term in partnership with generous donors and supporters. Our Board of Directors has ensured that our organization is well positioned to withstand this shock, and that we can continue to fund ground-breaking research and discovery taking place at The Princess Margaret despite the challenges presented by the pandemic. But we can’t stop there. We will need the sustained support of our donors and volunteers to ensure that sufficient funding exists to continue to create Future Care Now as we endure this global pandemic.

Cancer has not stopped because of COVID-19, and neither can we.

We are committed to strengthening our organization to elevate the impact of donor funds at Princess Margaret Cancer Centre and beyond, and we are driven to deliver on our aspiration to become Canada’s most respected charitable foundation where people want to give, work and volunteer.

We continue to believe that the most impactful place in the world that a donor can make an investment in Conquering Cancer is at The Princess Margaret. We thank our donors, volunteers, and community members for their continued support, and for partnering with us to enable Future Care Now at The Princess Margaret.
All Events Lead to the Same Finish Line
Together, we can Conquer Cancer In Our Lifetime

We did not become one of the top 5 cancer research centres in the world alone. We got here with the help of our growing community: fearless patients, thousands of world-class doctors and researchers, the loved ones who fill our waiting rooms and the friends that refuse to give up hope.

The vital funds raised through dedicated event participation each year are transformational. They allow us to develop cutting-edge treatments and globally recognized diagnostic tools, continuously fuelling the life-saving research that keeps us all focused on the finish line.

Thank you to our supporters who showed their Courage to Conquer by participating in some of the many events we have available that support The Princess Margaret.

Whether you run or walk 1 km, 3 km or 5 km, you will surely make a difference.
runorwalk.ca

Passionate gamers, making a difference while doing what they love.
questtoconquercancer.ca

Thousands play to raise millions in the world’s largest road hockey fundraiser, Scotiabank Road Hockey to Conquer Cancer.
roadhockeytoconquercancer.ca

There is no shortage of ways to contribute and a rainbow of colours to brighten somebody’s day.
colourtoconquer.ca

$32.4M
Total events revenue

$41.6M
Net lottery revenue

Every October, thousands of pink epaulettes are worn to support breast cancer research.
thepmcf.ca/events

Every year thousands of Ontarians purchase a lottery ticket for a chance to win great prizes.
princessmargaretlotto.ca

Enbridge® Ride to Conquer Cancer® is two days and over 200 km. We all ride for someone and this is one ride you’ll never forget.
conquercancer.ca

For 18 years our community of walkers, including corporate teams from across Canada, have come together to walk as one.
weekendtoconquercancer.ca

This is a cycling adventure built for those who prefer to take the scenic route.
northernpass.ca

Thousands play to raise millions in the world’s largest road hockey fundraiser, Scotiabank Road Hockey to Conquer Cancer.
roadhockeytoconquercancer.ca

There is no shortage of ways to contribute and a rainbow of colours to brighten somebody’s day.
colourtoconquer.ca

$32.4M
Total events revenue

$41.6M
Net lottery revenue
Global progress is often achieved through the leadership of people who come forward to create timely, evidence-based opportunities for the betterment of the entire country. This rings especially true with Michael McCain, CEO of Maple Leaf Foods, whose recent $10 million donation allowed Princess Margaret Cancer Centre to join forces with researchers at University of Toronto to develop a new landscape in urological health.

The McCain Centre for Urological Innovation and Education opened in June of 2019 and had a ground-breaking first year, thanks to Michael McCain’s vision and generosity. The McCain Centre is a multidisciplinary hub that has already given many highly skilled scientists the tools they need to advance research, training and clinical care while providing long-term support for U of T’s Surgeon Scientist Training Program. Within the first year, this centre along with the world class McCain GU (Genito-Urinary) Bio Bank, has significantly advanced our understanding of the bladder, prostate, kidney and testis.

With Michael’s support, we’ve generated 60 national and international partnerships, hired three surgeon-scientist trainees and submitted several significant grant applications to help explore new discoveries that will help patients that are affected by urological disease.

To further accelerate this research locally, the McCain GU Biobank, in collaboration with UHN, established PRESERVE (Pandemic RESponsible), UHN’s first biorepository for specimens from patients diagnosed with the new coronavirus. The samples collected provide valuable insights into key aspects of the disease while aiding with detection, prevention and treatment. These samples will be housed indefinitely to enable future research studies.

In March, as COVID-19 shut down the entire global economy and put a tremendous amount of pressure on Canadian healthcare systems, crucial supplies, support and research funding quickly became scarce. Maple Leaf Foods boldly stepped up to offer support with a new fund that has inspired thousands of others to follow suit.

The Frontline Fund was launched in April, when Maple Leaf Foods and its CEO, Michael McCain, brought The Princess Margaret Cancer Foundation together with hospital foundations across Canada. The national fund was established with the help of CanadaHelps to give corporate Canada and individual Canadians an opportunity to help protect frontline workers and deliver the many tools needed to help address the COVID-19 public health emergency. The coast-to-coast collaboration quickly became a one-stop solution for all Canadians who wanted to help, and Maple Leaf Foods set the bar high with a generous $2.5 million donation. To date, the fund has raised more than $11.5 million and helped support more than 140 hospitals across the country.

The Frontline Fund has provided many of the essential tools Canada’s healthcare workers desperately need, while accelerating the use of technology to enable virtual patient care. It helps many of the nation’s leading hospitals conduct clinical drug trials and develop potential vaccines. In addition, it offers peer-to-peer support as well as hospital-adjacent hotel rooms for exhausted frontliners battling the crisis.
Hold’em For Life is All-In

The Princess Margaret attracts hundreds of bright minds from all over the world who strive to become world leaders in cancer care. Our ability to nurture this upcoming generation of global cancer leadership is only possible through affiliation with events like Hold’em For Life.

The Hold’em For Life Charity Challenge, entirely volunteer-run, is an exclusive opportunity for business leaders to get together and play in a complete Monte Carlo-style poker tournament while contributing to life-saving cancer research. This year, Hold’em went all-in and reinforced their commitment to fostering our academic community by donating a transformational $16 million to research across GTA hospitals through the Hold’em For Life Oncology Clinician Scientist Award Fellowship. $10 million of which directly supports progress here at Princess Margaret Cancer Centre. This initiative will propel the future of cancer research forward by securing 40 clinical fellows each year.

This program is currently open to all University of Toronto’s clinical residents and fellows who may be pursuing a career in cancer research at any of U of T’s nine affiliated hospitals, including The Princess Margaret and Mount Sinai Hospital. Funds are then matched dollar-for-dollar by the institution in which the fellow resides, quickly doubling down on impact.

To date, many promising young researchers have already produced significant advancements in new treatments while expanding our understanding of response and resistance.

The support from the Hold’em team invites a breadth of knowledge into the Cancer Centre, while advancing the next generation of breakthroughs for doctors and researchers at The Princess Margaret. Their generosity has been a catalyst for many studies that have the potential to change the world, while giving 40 of the brightest young minds in medicine a reason to call Toronto home. They don’t just invest in research, they invest in the people who make our institution one of the top 5 cancer research centres in the world and will no doubt leave a lasting impact on the future of oncology. We thank the entire Hold’em For Life organization for the monumental role they continue to play in leading the way.

Congratulations to the following 2020/2021 Hold’em For Life fellows at Princess Margaret Cancer Centre:

Abi Vijenthira
The Gerald Schwartz & Heather Reisman Foundation Hold’em For Life Oncology Fellow
Project: Application of the generalizable frailty index using population-based health administrative data

Khaled Ramadan
Silverberg Hold’em For Life Oncology Fellow
Project: Photodynamic therapy during in vivo lung perfusion for treatment of lung metastases

Gregory Nason
CentreCourt Hold’em for Life Oncology Fellow
Project: Comparison of OpenN VErsus RoboTic (CONVERT) Partial Nephrectomy Trial—a feasibility randomized control trial

Lucy Liu
Onex Hold’em For Life Oncology Fellow
Project: The effect of intestinal microbiome on development of malignant bowel obstruction in advanced gynecologic malignancies

Irene Xie
CIBC Capital Markets Hold’em for Life Oncology Fellow
Project: Identifying molecular vulnerabilities in pancreatic cancer

Paulo Kayano
CBRE Hold’em for Life Oncology Fellow
Project: Impact of proton pump inhibitors on prostate cancer diagnosis and outcomes

Keegan Guidolin
CMCC/Atrium Hold’em for Life Oncology Fellow
Project: Porphysomes for the intraoperative visualization of colorectal lymph node metastases

Robert Grant
SmartCentres Hold’em for Life Oncology Fellow
Project: Predicting outcomes in pancreatic cancer from clinical and genomic data using machine learning

Donor Story: Hold’em For Life

The Princess Margaret attracts hundreds of bright minds from all over the world who strive to become world leaders in cancer care. Our ability to nurture this upcoming generation of global cancer leadership is only possible through affiliation with events like Hold’em For Life.

The Hold’em For Life Charity Challenge, entirely volunteer-run, is an exclusive opportunity for business leaders to get together and play in a complete Monte Carlo-style poker tournament while contributing to life-saving cancer research. This year, Hold’em went all-in and reinforced their commitment to fostering our academic community by donating a transformational $16 million to research across GTA hospitals through the Hold’em For Life Oncology Clinician Scientist Award Fellowship. $10 million of which directly supports progress here at Princess Margaret Cancer Centre. This initiative will propel the future of cancer research forward by securing 40 clinical fellows each year.

This program is currently open to all University of Toronto’s clinical residents and fellows who may be pursuing a career in cancer research at any of U of T’s nine affiliated hospitals, including The Princess Margaret and Mount Sinai Hospital. Funds are then matched dollar-for-dollar by the institution in which the fellow resides, quickly doubling down on impact. To date, many promising young researchers have already produced significant advancements in new treatments while expanding our understanding of response and resistance.

The support from the Hold’em team invites a breadth of knowledge into the Cancer Centre, while advancing the next generation of breakthroughs for doctors and researchers at The Princess Margaret. Their generosity has been a catalyst for many studies that have the potential to change the world, while giving 40 of the brightest young minds in medicine a reason to call Toronto home. They don’t just invest in research, they invest in the people who make our institution one of the top 5 cancer research centres in the world and will no doubt leave a lasting impact on the future of oncology. We thank the entire Hold’em For Life organization for the monumental role they continue to play in leading the way.

Congratulations to the following 2020/2021 Hold’em For Life fellows at Princess Margaret Cancer Centre:

Abi Vijenthira
The Gerald Schwartz & Heather Reisman Foundation Hold’em For Life Oncology Fellow
Project: Application of the generalizable frailty index using population-based health administrative data

Khaled Ramadan
Silverberg Hold’em For Life Oncology Fellow
Project: Photodynamic therapy during in vivo lung perfusion for treatment of lung metastases

Gregory Nason
CentreCourt Hold’em for Life Oncology Fellow
Project: Comparison of OpenN VErsus RoboTic (CONVERT) Partial Nephrectomy Trial—a feasibility randomized control trial

Lucy Liu
Onex Hold’em For Life Oncology Fellow
Project: The effect of intestinal microbiome on development of malignant bowel obstruction in advanced gynecologic malignancies

Irene Xie
CIBC Capital Markets Hold’em for Life Oncology Fellow
Project: Identifying molecular vulnerabilities in pancreatic cancer

Paulo Kayano
CBRE Hold’em for Life Oncology Fellow
Project: Impact of proton pump inhibitors on prostate cancer diagnosis and outcomes

Keegan Guidolin
CMCC/Atrium Hold’em for Life Oncology Fellow
Project: Porphysomes for the intraoperative visualization of colorectal lymph node metastases

Robert Grant
SmartCentres Hold’em for Life Oncology Fellow
Project: Predicting outcomes in pancreatic cancer from clinical and genomic data using machine learning

Donor Story: Hold’em For Life

The Princess Margaret attracts hundreds of bright minds from all over the world who strive to become world leaders in cancer care. Our ability to nurture this upcoming generation of global cancer leadership is only possible through affiliation with events like Hold’em For Life.

The Hold’em For Life Charity Challenge, entirely volunteer-run, is an exclusive opportunity for business leaders to get together and play in a complete Monte Carlo-style poker tournament while contributing to life-saving cancer research.

This year, Hold’em went all-in and reinforced their commitment to fostering our academic community by donating a transformational $16 million to research across GTA hospitals through the Hold’em For Life Oncology Clinician Scientist Award Fellowship. $10 million of which directly supports progress here at Princess Margaret Cancer Centre. This initiative will propel the future of cancer research forward by securing 40 clinical fellows each year.

This program is currently open to all University of Toronto’s clinical residents and fellows who may be pursuing a career in cancer research at any of U of T’s nine affiliated hospitals, including The Princess Margaret and Mount Sinai Hospital. Funds are then matched dollar-for-dollar by the institution in which the fellow resides, quickly doubling down on impact. To date, many promising young researchers have already produced significant advancements in new treatments while expanding our understanding of response and resistance.

The support from the Hold’em team invites a breadth of knowledge into the Cancer Centre, while advancing the next generation of breakthroughs for doctors and researchers at The Princess Margaret. Their generosity has been a catalyst for many studies that have the potential to change the world, while giving 40 of the brightest young minds in medicine a reason to call Toronto home. They don’t just invest in research, they invest in the people who make our institution one of the top 5 cancer research centres in the world and will no doubt leave a lasting impact on the future of oncology. We thank the entire Hold’em For Life organization for the monumental role they continue to play in leading the way.
Each year we break new ground in research and patient care thanks to the steadfast support of socially conscious Canadian companies like Agnico Eagle, that continue to give back while driving innovation forward.

For close to 25 years, Agnico has been setting the standard for corporate responsibility. Not only has the leadership team made socially and environmentally sound decisions a priority in the lives of their employees and communities, but they also remain committed to a vision that is shared by all of us: to Conquer Cancer In Our Lifetime. And thanks to a new $5 million gift, our world-class clinicians are currently running the number one immunotherapy program in the country, changing the way many cancers are treated around the world.

This isn’t just another fundraising initiative to Agnico. It’s personal. And it began in 1996 with Agnico Eagle founder Paul Penna, whose philanthropic spirit instilled a systemic and proactive approach for the entire organization. From that point on, many senior executives and board members who support The Princess Margaret—including Sean Boyd, Jim Nasso, Ammar Al-Joundi, Robert Gemmell, and David Smith—have become champions of corporate engagement, confident that their support will leave a lasting impression on a global stage.

“We are very fortunate to have The Princess Margaret, a globally recognized leader in cancer research and cancer care. This creates a tremendous opportunity for businesses in Canada to support world-class researchers and doctors with breakthrough discoveries and innovative treatments.”

—Sean Boyd

The Agnico team continues to help drive cancer care forward on many levels, not only through direct corporate giving, but also consistent personal philanthropic support, as well as fundraising with employees who volunteer their time to many of our events. In 2009, the Agnico team initiated an annual charity golf tournament that continues to raise over $200,000 each year in support of The Princess Margaret’s Head & Neck program. And the ‘Women in Mining’ team raises crucial funds every year through participation in OneWalk to Conquer Cancer. To take their commitment one step further, Jim Nasso took to the stage in 2018 for Humour Me, an evening comedy event benefitting The Princess Margaret.

Vice Chairman and CEO Sean Boyd has served on The Princess Margaret Cancer Foundation Board of Directors for a number of years. He and his wife Peta are generous donors and Sean continues to provide leadership across many Foundation initiatives. His input was instrumental in helping us achieve our Billion Dollar Challenge. Sean initiated the very first ‘Gold Bar Challenge’ in which Agnico donated $600,000 in gold to the Liquid Biopsy Program while encouraging other gold companies to do the same. Collectively, they have invested just over $3.2 million and significantly advanced our approach to early cancer detection.

In 2016, Agnico announced a critical $5 million investment in immunotherapy research. This donation helped fund 27 clinical studies, 18 of which were investor-initiated and nine that were geared towards understanding the microenvironment of the tumour and immune response. Since more than half of the clinical trials at The Princess Margaret in the last two years have involved immunotherapy, this gift has helped us revolutionize the ways many cancers are treated and is already saving and prolonging the lives of patients who otherwise would have been lost to cancer.

Agnico Eagle shares our belief that corporate social responsibility should not be a choice, but rather an essential part of any business strategy to meet the needs and expectations of all stakeholders. As businesses look to prioritize their social investment opportunities, they are undoubtedly focused on where they can have the greatest impact. As one of the top 5 cancer research centres in the world, we believe The Princess Margaret is the best place in the world to invest in the future of cancer care benefitting patients both locally and around the world.

We are deeply grateful for the ongoing support of Agnico Eagle and its employees. With corporate partners who follow the Agnico lead, we will Conquer Cancer In Our Lifetime.
Thank You,
Dr. Mary Gospodarowicz

This May marked the end of an era as Dr. Mary Gospodarowicz, Medical Director of Princess Margaret Cancer Centre, stepped down after 15 years of leadership.

Over the course of her time in this monumental role, Dr. Gospodarowicz helped elevate the national and global prestige of this institution. She has vastly increased the ability to deliver outstanding care to thousands of patients, was instrumental in advancing many areas of clinical research, and was the voice of The Princess Margaret on many of the biggest stages in the world. Her influence helped to shape cancer care and public policy here in Canada and across the globe.

During her tenure, Dr. Gospodarowicz helped to establish the Young Leaders in Cancer Program for UHN, which supports and develops emerging leaders in the global cancer community. She was the first Canadian President of the Union for International Cancer Control (UICC) and in this role, created a Global Task Force on Radiotherapy for Cancer Control (GTFRCC) that later became the Lancet Oncology Commission on Radiotherapy for Cancer Control.

In addition to all of Dr. Gospodarowicz’s accolades and awards, she is also respected for her humanity, generosity and kindness, over the years forging incredible bonds with donors, her patients and their families. Dr. Gospodarowicz was engaged in our fundraisers and served on our Board of Directors for 15 years.

Dr. Gospodarowicz was an advocate for all sides of patient care and the heart behind many big milestones, including a $50 million Space Transformation and the record-setting Billion Dollar Challenge. Dr. Gospodarowicz believed that The Princess Margaret could be the very best cancer centre in the world and worked tirelessly to facilitate Future Care Now.

Thank you for your incredible legacy, Dr. Gospodarowicz! Your work will continue to inspire many bright minds here in Canada and around the world, well into the future.

Welcome Back,
Dr. Keith Stewart

Princess Margaret Cancer Centre welcomes back renowned multiple myeloma clinician and researcher, Dr. Keith Stewart.

This year, Dr. Stewart rejoined as Medical Director of the Princess Margaret Cancer Program, Vice President, Cancer, UHN, and Regional Vice President, Toronto Central South Regional Cancer Program, Ontario Health (Cancer Care Ontario).

Dr. Stewart began practicing at Toronto General Hospital (TGH) in 1992, subsequently moving his clinical practice to The Princess Margaret in 1999. While at UHN, he became the first Research Director at TGH, began the University of Toronto McLaughlin Centre for Molecular Medicine, and conducted the first viral gene therapy clinical trials in Canada.

UHN prepared him well for the move to the Mayo Clinic in 2005, where he was the Director of the Mayo Clinic Center for Individualized Medicine. This center focuses on genome-based research and clinical implementation, customizing care to a patient’s unique genetic makeup.

As a scientist, Dr. Stewart has more than 25 years of sustained national funding for a laboratory research program in genomics and biology of multiple myeloma, and has led many clinical trials of new drugs for this blood cancer.

Dr. Stewart stresses that cancer care for generations to come will require a fearless vision: detecting cancer early while it is still curable; developing high-definition, precision treatments to replace outdated treatments with debilitating side effects; using Artificial Intelligence to discover unexpected links and patterns within cancer for better detection; and creating comfort and confidence for both staff and patients.

He hopes that he can help streamline cumbersome administrative practices and support staff who could better spend their time with patients, reflecting on their next projects, building strong, diverse teams and practicing wellness.

Congratulations and welcome back, Dr. Stewart!
Looking Back and Moving Forward: Cancer Centre Key Initiatives

Princess Margaret Cancer Centre launched a new strategic plan in 2019, Future Care Now: Create Cancer Care for 2030. A plan designed to ignite new paths in discovery and maintain a strong global momentum in care. Several key programs were built to achieve this goal, two of them being The Princess Margaret Data Science Program (PMDSP) and the Global Cancer Program.

The Princess Margaret Data Science Program leverages multidimensional, high-quality data to gain a deeper understanding of complex cancers. The progress made in computerization and data science allows the team to utilize rich data assets to identify effective therapies, predict outcomes and prevent toxicities. This innovative program was built to breed cross-specialty collaboration by utilizing a group of diverse data sources to fuel learning and help uncover previously undetectable trends in cancer care.

The program is co-led by a diverse and distinguished group of cancer experts, including Tran Truong, Program Director, Dr. Benjamin Haibe-Kains, Scientific Lead, Dr. Alejandro Berlin, Clinical Lead, and Luke Brzozowski, Partnership Lead.

The Global Cancer Program, directed by Dr. Danielle Rodin, was established to ensure cancer care is available to patients, families and communities throughout the world. Serving as an international hub to discuss leading research surrounding the many economic and social factors that influence treatment, the program will continue to forge dynamic international partnerships and will soon be hosting leaders from across the country to further define Canada’s role in global oncology. “We share our knowledge, yes, but we also learn about new models of care and how to be nimble from our international partners,” says Dr. Rodin.

These are just two key initiatives that continue to set the Foundation up for long-term success and allow the scientists and researchers at The Princess Margaret to unleash their unlimited potential.

Yamana Gold: Making an Entrance

This year Yamana Gold elevated their long time support of The Princess Margaret with a $1 million gift to the space transformation campaign. This generous gift has funded the new Accessibility Entrance on University Avenue, and will allow all patients and families safe passage into the newly renovated cancer centre. We thank Yamana Gold for their continued support of research and care at The Princess Margaret.

To Transform Cancer Care Around the World, We Had to Start Here

Four years ago, we embarked on our most ambitious renovation to date. A $50 million space transformation that was consciously designed to improve and empower the lives of everyone who visits Princess Margaret Cancer Centre. And while COVID-19 did not come without its set of unique challenges, we are proud to report we are moving ahead as scheduled.

We have opened our fully renovated blood lab, outpatient pharmacy, cancer education centre and several new comfortable lounges throughout the main floor to improve the patient experience on each visit to the Cancer Centre.

The bright and timely revitalization will support families as they take their healing journey together and encourage confidence at each stop along the way.

We were designed to serve only 7,000 new patients a year and have since evolved into a trusted global care leader, with close to 20,000 new patients annually. This state-of-the-art transformation is part of a multi-phase capital redevelopment plan for the Cancer Centre. With an expansion of our cellular therapy program and renovation of several clinics on the horizon, our work to transform the Cancer Centre will be completed over the next few years.

We will continue to enable Future Care Now through all areas of the Cancer Center and learn from every patient experience.

A Thank-You That Will Last a Lifetime

By supporting this space transformation, your impact will be realized for decades to come by the hundreds of thousands of people from all over the globe.
Invest in Research

Our researchers and scientists demonstrate the Courage to Conquer by challenging traditional thinking to create the future of cancer care. Their work spans the cancer continuum from early diagnosis, to the development of new drugs and therapies, to improving the experience of living with cancer—but without seed-funding, many of these ideas can stall.

All advancements in research have the potential to yield immense impact, but what is unique about this program is that it funds higher risk research that has the potential for much higher rewards. These generously allocated grants fund many early stage, high risk ideas that lack traditional means of funding. Thanks to our donors, each year two grant recipients receive $100,000 to embark on their bold and innovative ideas through the support of the Invest in Research program.

Donors not only get to fuel cutting-edge cancer care with the potential to save lives around the world, but all donors are then invited to come together and work directly with some of the brightest minds at The Princess Margaret to vote on which project they believe will have the greatest impact in the fight against cancer. Through this exclusive voting process, it is decided which research initiatives will receive one of these prestigious grants.

These projects are not incremental, but exponential, and have the potential to change the cancer game for decades to come.

Thanks to donor support, Drs. Marianne Koritzinsky and Phedias Diamandis have both received funding this year to support their high-risk, high-reward research. Dr. Koritzinsky is leading a project which aims to better understand the biology underlying pancreatic cancers, while Dr. Diamandis is working to develop new drugs that will be used to treat highly aggressive brain cancers. Through the power of donor commitment, the Invest in Research program has raised more than $2 million to date and the subsequent initiatives have secured $36 million of additional funding for new discoveries.

To date we have funded 22 projects, each one holding promise that is helping us create Future Care Now at The Princess Margaret.

“This program provides an important opportunity to collaborate and test new ideas that can lead to extraordinary insights and discoveries. When we invest in research we invest in our patients, and our people.”

—Dr. Aaron Schimmer, Director of Research, Princess Margaret Cancer Centre

Ready to Invest? Contact Karina Wong, Manager, Leadership Giving, karina.wong@thepmcf.ca or 416-946-6560 | Learn more about the impact of seed-funding at: thepmcf.ca/investinresearch

Look Who’s Leading the Way

The Till & McCulloch Paper of the Year Award winners are selected from nominees who exemplify the breadth and quality of research being done at The Princess Margaret. Congratulations to our 2019 winners!

(Basic Science)
Dr. Housheng Hansen He, PhD
Senior Scientist, Princess Margaret Cancer Centre

A rarely studied type of genetic material—known as circular RNA—has been revealed to be prevalent in prostate cancer. Dr. He and his team used ultra-deep sequencing to define the circular RNA present within 144 tumours and identified over 76,000 circular RNAs—more than 30,000 of which had not been previously described. They also found that the most aggressive types of prostate cancer tended to have abnormal production of circular RNAs and that a subset of circular RNAs are important for tumour growth, making them potential targets for RNA-based therapies. They are now testing whether circular RNAs can serve as markers to help diagnose prostate cancer earlier and predict whether it will come back or spread.

(Translational)
Dr. Danielle Rodin, MD, MPH, FRCPc
Clinician Investigator, Radiation Oncologist, Princess Margaret Cancer Centre

More than half a million women are diagnosed with cervical cancer each year, and the prevailing ideology has been that HPV vaccinations will eliminate the need for significant investment. Dr. Rodin and her team conducted a study on the benefits of external beam radiotherapy and brachytherapy. They found that by 2035, radiotherapy scale-up would save 11.4 million life-years. Their report is the first coordinated cervical cancer strategy that combines both prevention and treatment and is now being used to advocate for the inclusion of radiotherapy globally. A treatment target (90% access to cervical cancer treatment worldwide) was in the draft resolution being ratified at the World Health Assembly in Geneva in May 2020.

(Clinical)
Dr. Thomas Kislinger, PhD
Senior Scientist, Princess Margaret Cancer Centre

Prostate cancer is the most common non-cutaneous tumour in men but has minimal targeted therapies available. As a result, it remains an urgent research priority to identify candidate drug targets and molecular biomarkers while tumours are still curable by local therapy. Thomas Kislinger and his team published the first comprehensive proteogenomic analysis of prostate cancer, which merges complete understanding of a tumour’s genome with how that genome becomes expressed into functional proteins. The work of Kislinger and his team, in collaboration with the Boutros lab at UCLA, will serve as a platform for hundreds of other studies, contains several key findings and is the first study that directly quantifies the utility of multi-omic markers in any type of tumour.

The work of Kislinger and his team, in collaboration with the Boutros lab at UCLA, will serve as a platform for hundreds of other studies, contains several key findings and is the first study that directly quantifies the utility of multi-omic markers in any type of tumour.
The year has been full of hard work, passion, grief and hope. We came together to raise funds that accelerate cancer research, education and clinical care benefiting patients at Princess Margaret Cancer Centre, across Canada, and around the world.

We’d like to celebrate some of the many ways our donors supported The Princess Margaret Cancer Foundation over the year.

1. Fall 2019 Home Lottery winner, Maxine Ng  
2. Margaret + George do La Dolce Vita  
3. Doves of Hope  
4. Enbridge® Ride to Conquer Cancer®  
5. Team Multiple Myeloma - Journey to Conquer Cancer  
6. The Michelangelo Cup  
7. Behind the Scenes Event  
8. Scotiabank Road Hockey to Conquer Cancer  
9. A1 Radiothon

Thank you to everyone for supporting our vision to Conquer Cancer In Our Lifetime.
The Till & McCulloch Society was created to recognize supporters who have cumulatively contributed $1 million or more to advance cancer research and care at Princess Margaret Cancer Centre.

Founded in 2015, this Society is named in honour of Dr. James Till, a biophysicist, and Dr. Ernest McCulloch, a haematologist – researchers who pioneered stem cell science when they discovered the blood-forming stem cell at The Princess Margaret in the 1960s. This seminal work subsequently led to the advancement of many other discoveries in medicine such as bone marrow transplantation.

Like these remarkable scientists, members of the Till & McCulloch Society, through their significant financial contributions, have helped accelerate cancer research and care solidifying The Princess Margaret as one of the top 5 cancer research centres in the world. We are grateful to all of the individuals, corporations and foundations listed for their vision and passion to help Conquer Cancer In Our Lifetime.

To honour their tremendous support, members of the Society have the opportunity to attend exclusive events with Cancer Centre leadership, and they are the first to receive updates and information.

In late November of 2019, the Till & McCulloch Society were invited to an intimate cocktail reception hosted by Janice Fukakusa, Board Chair, and Michael Burns, President & CEO. The evening’s conversation centered around new discoveries and cutting-edge research while featuring some of the brightest minds in cancer care: Dr. Aaron Schimmer, Research Director, Princess Margaret Cancer Centre, Dr. Stéphanie Lheureux, Gynecology Site Lead, Dr. Brian Raught, Canada Research Chair in Proteomics and Molecular Medicine and Dr. Catherine O’Brien, Gastrointestinal Surgeon-Scientist.

We gratefully acknowledge the Till & McCulloch Society for their support and commitment to improve care and advance cancer research at Princess Margaret Cancer Centre.

For more information about the Society, please contact Christine Brown at christine.brown@thepmcf.ca | 416-946-6560.
Sharon Mohip:
Forever Helping to ‘Shake the Disease’

Sharon participated in her first 60 km, two-day walk supporting The Princess Margaret to honour her best friend’s mom back in 2008, on a team now called ‘Shake the Disease.’ The energy of the community kindled a lasting commitment, and for the following decade, Sharon continued to participate in OneWalk to Conquer Cancer while raising funds for many different areas of cancer research. However, it wasn’t until 2017 that her reasons for participating really hit home. That fall, Sharon’s mother, Parbattee, experienced a shortness of breath along with a cough that just wouldn’t go away. Her family doctor discovered fluid around her lungs and upon the preliminary diagnosis, at the family’s request, immediately referred her to the lung clinic at The Princess Margaret where Sharon’s family received a diagnosis that was very hard to digest. Parbattee had stage four metastatic lung cancer.

In early 2019, the cancer metastasized and moved from the lungs to the brain. Parbattee then shifted through several different specialties within The Princess Margaret, including neurology, radiation and eventually, palliative care. “Chemotherapy kept her stable for about 15 months, but once it moved to her brain things went very quickly,” Sharon said. In March of 2019, after a year-and-a-half long battle with cancer, Parbattee passed away peacefully in her sleep. Sharon says that the sincerity from the entire team helped her and her family make some very tough calls along the way. And for that she is forever grateful. “They always looked past the illness and into the person,” Sharon said. “When you really see it in action, the personalized treatments, the level of care, it really validates the effort you put into fundraising.”

Sharon and her father, Anthony, have both left legacy gifts to The Princess Margaret in their wills and she plans to continue fundraising until someone says she can’t. “It is one of the top 5 cancer research centres in the world; we know it will continue to make an impact on a global level.”
In 2007, Karen Maidment, a successful CFO and mother of two, looked into her office mirror and noticed her face was swollen. She thought it might be an allergic reaction but quickly found herself in the ER. Karen had an aggressive form of Non-Hodgkin’s Lymphoma—and like many others, was diagnosed without warning. She spent close to a year at The Princess Margaret undergoing chemotherapy and radiation while everything else came to a screeching halt. It was the fight of her life and fortunately, it was successful. During treatments, a clinical trial piqued Karen’s interest in medical research. “The feedback loop between clinic and research is strong; it continually turns and flows. I think that’s why The Princess Margaret has made so much global progress,” she said. In 2009, wanting to give back, Karen joined The Foundation’s Board of Directors. “The Board is made up of an outstanding group of people. I’ve served on many NFP boards in my time, but every single person here has a real determination and a singular focus: Conquer Cancer.”

While working to regain strength, a friend challenged her to participate in the Enbridge® Ride to Conquer Cancer®—a 200 km ride from Toronto to Niagara Falls in support of The Princess Margaret. “I haven’t ridden a bike in 40 years!” Karen replied. On the first day of training she made it past three houses, and then around the block, and eventually, with the support of her family and a few close friends, she completed her first official Ride. She recalls every kilometre (and the heat) like it was yesterday. “I remember thinking, I’m never doing this again,” she laughed. But in 2019, when her term on the Board was coming to an end, she decided it was time to get back on the bike and make Ride history with a fundraising goal of $500,000. The support of Karen’s family strengthened her resolve and the pitch was simple: “Your money is not going to a Toronto cancer hospital. It’s going to a global cancer leader that is making world-class advances in cancer care.” ‘Team Karen’ raised an astonishing $590,000.

She remembers having a discussion with Dr. Mary Gospodarowicz about where the funds could make the greatest impact, and she was then introduced to Dr. Alejandro Berlin, head of our Smart Cancer Care program. This burgeoning program uses the best in digital technology and specialized software to streamline delivery of virtual care. And while COVID-19 put many initiatives around the world on hold this year, an urgent need to keep our patients safe meant the Smart Cancer Care program was kicked into high gear. In just 11 days, the Smart Cancer Care team designed and launched a new system that enabled virtual visits, keeping patients connected to loved ones far and wide while reducing over 500 in-person visits per day. This was all possible due to the generosity of our donors and participants, like Karen, who helped fund this important initiative. We’d like to thank Karen for her longstanding commitment to our mission and for seed-funding a dramatic shift in how we deliver Future Care Now.

The Journey to Conquer Cancer brings thousands together each year with a shared vision to Conquer Cancer In Our Lifetime. One team that helps keep that dream alive is Multiple Myeloma: M-Moving Together Toward the Cure.

This year marks 16 years of determination for this renowned group of Multiple Myeloma benefactors, assembled by Cindy Leder, who got involved with The Cancer Centre when husband, Harley Ulster, was diagnosed. Cindy’s passion for the cause is contagious and has inspired many others who have been personally affected to join.

One of those inspired by Cindy was Sass Khazzam, who jumped on board in 2015, after wife Sharmeen was diagnosed. He took the ground running because he knows the funds raised will continue to make a difference for so many. “There is no cure, but my wife is benefiting from the fundraising and research that has been done to date. She will live longer than someone who may have been diagnosed 10 years ago because families back then planted a seed. And in order to conquer this disease we need to keep going.”

In addition, Molly Bloom joined, whose husband David had connected with Cindy after being diagnosed. “Cindy is an advocate like I’ve never seen in my life,” she said. When David Bloom succumbed to Myeloma complications in 2016 it only stoked the team’s fire for fundraising. “We will do whatever we have to do to support this research. I made a promise to David that I would continue to help find a cure,” Molly said.

The MM5K committee is passionate about fundraising for this treatable but still incurable blood plasma cancer and has raised a cumulative $6 million to date for Myeloma research, making it the largest fundraiser for Multiple Myeloma Research in Canada. These funds have contributed to research and treatment, as well as establishing The Molly and David Bloom Chair, the very first Multiple Myeloma Chair in Canada. This chair, held by Dr. Donna Reece, has given The Princess Margaret an opportunity to explore new research avenues, develop drugs that lengthen remissions and ultimately, new ways to extend the lives of those living with this disease while offering the best care possible.

It is estimated that in 2020, roughly 3,400 Canadians will be diagnosed with Multiple Myeloma and 1,600 Canadians will die from it. We are extremely grateful to be walking with MM5K year after year, toward a cure and thank everyone on the team for their dedication.
Statement of Revenue, Expenses and Changes in Fund Balances ($ Thousands)

<table>
<thead>
<tr>
<th>Year ended March 31</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Fundraising Revenue</td>
<td>96,815</td>
<td>95,202</td>
<td>98,590</td>
<td>91,822</td>
<td>122,861</td>
</tr>
<tr>
<td>Direct Fundraising Expenses1</td>
<td>(16,793)</td>
<td>(14,990)</td>
<td>(16,237)</td>
<td>(21,998)</td>
<td>(24,434)</td>
</tr>
<tr>
<td>Net Fundraising</td>
<td>79,022</td>
<td>80,212</td>
<td>82,353</td>
<td>69,824</td>
<td>98,427</td>
</tr>
<tr>
<td>Gross Lottery Revenue</td>
<td>70,947</td>
<td>72,334</td>
<td>78,897</td>
<td>88,239</td>
<td>102,304</td>
</tr>
<tr>
<td>Direct Lottery Expenses</td>
<td>(46,153)</td>
<td>(44,640)</td>
<td>(49,170)</td>
<td>(54,627)</td>
<td>(61,322)</td>
</tr>
<tr>
<td>Net Lottery</td>
<td>24,794</td>
<td>27,694</td>
<td>29,727</td>
<td>33,612</td>
<td>41,582</td>
</tr>
<tr>
<td>Net Fundraising and Lottery Revenue</td>
<td>103,816</td>
<td>107,906</td>
<td>112,080</td>
<td>103,436</td>
<td>140,009</td>
</tr>
<tr>
<td>Investment Income (Loss)</td>
<td>(1,660)</td>
<td>45,006</td>
<td>31,561</td>
<td>36,964</td>
<td>(5,153)</td>
</tr>
<tr>
<td>Net Revenue, including Investment Income</td>
<td>(102,156)</td>
<td>152,912</td>
<td>143,641</td>
<td>140,400</td>
<td>134,856</td>
</tr>
<tr>
<td>General Fundraising and Administrative Expenses2</td>
<td>10,724</td>
<td>11,287</td>
<td>12,467</td>
<td>9,603</td>
<td>9,743</td>
</tr>
<tr>
<td>Excess of Revenue over Expenses before Grants</td>
<td>91,432</td>
<td>141,625</td>
<td>131,174</td>
<td>130,797</td>
<td>125,113</td>
</tr>
<tr>
<td>Grants to Princess Margaret Cancer Centre</td>
<td>3,048</td>
<td>3,724</td>
<td>8,552</td>
<td>9,635</td>
<td>8,661</td>
</tr>
<tr>
<td>Research, Education and Patient Care</td>
<td>85,276</td>
<td>89,118</td>
<td>95,928</td>
<td>93,169</td>
<td>92,998</td>
</tr>
<tr>
<td>Equipment</td>
<td>8,137</td>
<td>9,618</td>
<td>2,083</td>
<td>1,868</td>
<td>4,122</td>
</tr>
<tr>
<td>Excess of Revenue and Grants for the year</td>
<td>(5,029)</td>
<td>39,165</td>
<td>24,611</td>
<td>26,125</td>
<td>19,332</td>
</tr>
<tr>
<td>Total gross fundraising revenue</td>
<td>$225.8 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross fundraising revenue</td>
<td>$122.9 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fundraising expenses</td>
<td>$24.4 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net fundraising revenue</td>
<td>$98.5 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net lottery revenue</td>
<td>$41.6 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lottery prizes</td>
<td>$36.8 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marketing and other expenses</td>
<td>$24.5 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lottery revenue</td>
<td>$102.9 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net revenue = $140.0 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Financial Summaries

5-Year Overview

Each year, The Princess Margaret Cancer Foundation reports on the funds it raises and stewards in two ways: via Audited Financial Statements (AFS) online at www.thepmcf.ca, and via the standard CRA T3010 form required of all not-for-profit organizations and found on the CRA website at canada.ca/en/services/taxes/charities.html. While both formats utilize the same financial information, The Foundation’s AFS provides a more detailed look to better assess and control our financial performance.

Fiscal 2020

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer In Our Lifetime.

Fulfilling our Mission

We enable Future Care Now by raising funds that accelerate cancer research, education, and clinical care benefiting patients at Princess Margaret Cancer Centre, across Canada, and around the world.

Statement of Revenue, Expenses and Changes in Fund Balances ($ Thousands)

Note 1. Direct fundraising expenses represent costs for logistics, marketing and other expenses directly related to fundraising activities, including our major events such as Enbridge ® Ride to Conquer Cancer ®, OneWalk to Conquer Cancer and our Direct Marketing programs.

Note 2. General fundraising and administrative expenses are the overhead costs associated with running Foundation operations.

Notes

Year-over-year highlights

<table>
<thead>
<tr>
<th>Year-over-year highlights</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net fundraising and lottery revenue ($ millions)</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
</tr>
<tr>
<td>Total gross fundraising revenue</td>
<td>$225.8 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants provided to Princess Margaret Cancer Centre ($103.8 million)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research, Education, Patient Care</td>
<td>88%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building</td>
<td>8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment</td>
<td>4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Year-over-year highlights

<table>
<thead>
<tr>
<th>Year-over-year highlights</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net fundraising and lottery revenue ($ millions)</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
</tr>
<tr>
<td>Total gross fundraising revenue</td>
<td>$225.8 million</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants provided to Princess Margaret Cancer Centre ($103.8 million)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research, Education, Patient Care</td>
<td>88%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building</td>
<td>8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment</td>
<td>4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fiscal 2020

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer In Our Lifetime.

Fiscal 2020

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer In Our Lifetime.

Fiscal 2020

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer In Our Lifetime.
A Chair is the highest honour in academic life, prestigious for Chairholder and donor alike. Our Chairholders are recognized internationally for superior academic achievement, experience and success in teaching and research.

**CHAIRS**

- AMGEN Chair in Cancer Research
  - Dr. Robert Rottapel
- Bartley-Smith Wharton Chair in Radiation Oncology
  - Dr. John Waldron
- Daniel E. Bergsagel Chair in Medical Oncology
  - Dr. John V. deKernion
- M. G. Sciotto Chair in Lung Cancer Translational Research
  - Dr. Ming S. Tsao
- BMO Financial Group Chair in Precision Genomics
  - Dr. Lillian Siu
- Poulin Chair in Genomics
  - Dr. Geoffrey Liu
- Dr. Marlene Antonio Ellis Chair in Head and Neck Cancer Research
  - To be appointed
- McLean/Taylor Chair in Kidney Cancer Research
  - Dr. Antonio Fossi
- Drey and Mary Fidani Family Chair in Radiation Physics
  - To be appointed
- Saba Chair in Breast Surgical Oncology
  - Dr. Tuhin Chaudhuri
- Peter and Shoshana Goldstein Chair in Radiation Medicine
  - Dr. Fei-Fei Liu
- PhD in Unico Chair in Oncology Pathology
  - To be appointed
- K. Y. Ho Chair in Prostate Cancer Research
  - To be appointed
- Koenig Family Chair in Neuro-Oncology Research
  - Dr. Warren Wilson
- Lee K. and Margaret Lou Chair in Breast Cancer Research
  - To be appointed
- Hamid and Shirley Laderman Chair in Psychosurgical Oncology and Palliative Care
  - Dr. Gary T. Rodin
- Wilfred S. Lawley Chair in Pancreatic Cancer Research
  - Dr. Jennifer J. Knox
- The Lowe Chair in Prostate Cancer Prevention Research
  - To be appointed
- The Ashley Macnaughton Chair in Therapeutic Radiation Oncology
  - Dr. Alexander Sun
- Guttman Family/U of T Family Chair in Obstetrics/Obstetrics/Neonatology
  - Dr. Ralph G. Gibbeth
- Phillips Chair in Leukemia Research
  - Dr. Mark M. Allday
- OSF Pharmaceuticals Foundation Chair in Cancer Next-Generation Drug Development
  - Dr. Natasha B. Leighl
- RBC Chair in Nursing Oncology
  - Dr. Samantha Majo
- R. Howard Webster Foundation Chair in Medical Imaging and Artificial Intelligence
  - To be appointed
- Kevin and Sandra Sullivan Chair in Neuro-Oncology
  - Dr. Jonathan C. Irish
- Joey and Toby Terner/Twain/Bradley Bell Chair in Prostate Cancer Research
  - Dr. Gang Zheng
- St. John's/Weizsacker Chair in Image Guided Prostate Therapy Research
  - Dr. Fred Schmitt
- Westin to End Breast Cancer Chair in Breast Cancer Research
  - Dr. Tuhin Chaudhuri
- Westin to End Ovarian Cancer Research
  - To be appointed
- The Robert E. Wharton Chair in Head and Neck Surgery
  - Dr. Patrick J. Gullane
- The Robert E. Wharton Chair in Reconstructive Plastic Surgery
  - Dr. Stefan G. Hoyer

**JOINT CHAIRS AT UNIVERSITY HEALTH NETWORK**

- Silver and Seymour Epstein Chair in Cell Therapy and Transplantation
  - To be appointed
- The Alan and Susan Hudson Chair in Neuro-Oncology
  - Dr. Fred Guttell
- Pearson/Whittington Chair in Thoracic Surgical Oncology
  - Dr. Shaf Keshavjee
- Scotiabank Research Chair
  - Dr. David Brooks
- Fick/Senecioza Chair in Prostate Disease
  - To be appointed
- Scott Taylor Chair in Lung Cancer Research
  - Dr. Frances A. Shepherd
- Gerald Scott/Donald C. Whitmore Chair in Hematology and Gene Therapy Research
  - To be appointed

**Board of Directors**

University Health Network (UHN)
April 1, 2019 to March 31, 2020

**Chairs**

- Brian J. Porter, Board Chair
  - UHN Board of Trustees

**Elected Trustees (Voting)**

- Brian J. Porter
- Ross Baker
- Dean Connor
- Todd Halpern
- Stu Kedwell
- Doug McGregor
- Peter Munkes
- Lawrence Pentland
- Janet Rossant
- Shirlee Sharkey
- Barbara Stymiest
- Peter Wallace
- Jaime Watt
- Cornell Wright

**Ex Officio Trustees (Non-Voting)**

- Kevin Smith
- Cheryl Regehr
- Mark Osten
- Fai-Fai Liu
- Raj Kothari

**Trustees Appointed by U of T Governing Council (Voting)**

- Trevor Young

**Ex Officio Trustees (Non-Voting)**

- Joy Richards
- Jane B. Smith
- John G. Smith
- Mark Osten
- Raj Kothari

**Ex Officio Trustees (Non-Voting)**

- Fei-Fei Liu
- Chair of the Medical Advisory Committee
- Janice Fukakusa
- Chair of the Princess Margaret Foundation Board
- Raj Kothari
- Chair of the Toronto General & Western Hospital Foundation Board

**Board Chair**

- Brian J. Porter, Board Chair, UHN Board of Trustees
Lara Brown: Determined to Tell Her Story

Lara Brown was standing outside of gate one at Scotiabank Arena when she heard the words “breast cancer” from the other end of the phone. She was 37 years old.

Lara, an active, healthy and recently divorced mother of two was “beyond exhausted.” She sells executive suites to The Princess Margaret under the care of Dr. Bedard. “I knew two people that were treated there, I knew it was my best option,” she said.

During chemo, she did five spin classes a week. When she wasn’t spinning, she ran...sometimes to appointments. And after just nine treatments, against her parents’ wishes, ran the Scotiabank half marathon. She experienced little to no side effects from treatment and managed to stand up against a drug that has the power to knock many others down.

“I refused to ask, ‘why me?’ because it was me,” Lara said. “I knew there were two paths this diagnosis could take; this was my story and I was going to tell it my way.”

The 21 days of radiation didn’t stop her either. “It left my skin raw, so I’d wear three bras to make sure nothing bled when I ran,” Lara said. When it was done, she hired a coach and started training—as she pushed through the lingering side effects and prepped for her final procedure, she asked “When can I swim, bike and run?”

Lara began each appointment with the following two questions: “Can I run?” and “Can I have a glass of wine?” Dr. Bedard wasn’t opposed to the running but said to make sure it was always a good wine. However, her radiologist, Dr. Liu, advised walking instead, mainly due to the low energy levels that often came with chemo treatments. What Dr. Liu didn’t realize is that Lara Brown does not have a walk button, and in that moment, decided she was going to be unlike any other patient before her and finish an Ironman. “You can’t tell a runner to walk,” Lara said.

Our thanks are also extended to the following individuals from our community of supporters who also serve on committees of The Princess Margaret Cancer Foundation:

Our thanks are also extended to the following individuals from our community of supporters who also serve on committees of The Princess Margaret Cancer Foundation:

Cecile Chung
Bob Dorrance
Tom Ehrlich
Stephen Guldhar
Marianne Harris

Helen Mallevoy Hicks
Lorraine Kirchmann
Neville Kirchmann
Maureen Shaughnessy Kitts
Angela McDonald

Wendy Posluns
Tina Tehranchian
Michael S. Wilson
Betsy Wright

Page 34
Board Committees
The Princess Margaret Cancer Foundation
April 1, 2019 to March 31, 2020

BOARD COMMITTEE | LEADERSHIP | MEMBERSHIP
--- | --- | ---
Commercialization | Chair: Stuart Waugh (2023) | Rohit Bhatkar (2026) Janice Fukakusa (2020) J-F Courville (2018) Brad Wouters (UHN) Dr. Aaron Schimmer (Research Director, PM Cancer Centre) Executive VP Technology & Innovation, UHN (Vacant) Angela McDonald (Community) Glenn Iwas (Community) Mark Taylor (UHN)
HR & Compensation | Chair: David Shaw (2022) | Janice Fukakusa (2020) Michael Worb (2027) Stacey Madge (2027)

BOARD COMMITTEE | LEADERSHIP | MEMBERSHIP
--- | --- | ---
Investment | Chair: Richard Rooney (2026) | Terry Bacinello (2026) Janice Fukakusa (2020) Andrew Hoffman (2025) Stuart Waugh (2023) Bob Dorrance (Community) Stephen Goudar (Community) Marianne Harris (Community) Arish Chopra (Community) joined June 1, 2020 Azar Zafar (Community) joined June 1, 2020

Note: Janice Fukakusa, Board Chair is member of all Board Committees.

UHN Governance Appointments

<table>
<thead>
<tr>
<th>COMMITTEE</th>
<th>ROLE</th>
<th>NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>UHN Board of Trustees</td>
<td>Board Chair</td>
<td>Janice Fukakusa</td>
</tr>
<tr>
<td>UHN Finance &amp; Audit Committee</td>
<td>Chair, Audit &amp; Risk Committee</td>
<td>Annie Ropar</td>
</tr>
<tr>
<td>UHN Research Committee</td>
<td>Chair, Granting, Stewardship &amp; Impact</td>
<td>Sean Boyd</td>
</tr>
</tbody>
</table>